Terms ending in 2031
Every in-force patent on Abraxis Bioscience, LLC's record whose computed term ends in 2031, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,370,494 | Methods for Treating Hepatocellular Carcinoma In force · High confidence | Abraxis Bioscience, LLC | In force | High confidence | |
| US 9,820,949 | Methods of Treatment of Pancreatic Cancer In force · Medium confidence | Abraxis Bioscience, LLC | In force | Medium confidence | |
| US 10,660,965 | Methods of Enhancing Drug Delivery and Effectiveness of Therapeutic Agents In force · High confidence | Abraxis Bioscience, LLP | In force | High confidence | |
| US 9,399,071 | Methods of Treatment of Pancreatic Cancer In force · High confidence | Abraxis Bioscience, LLC | In force | High confidence | |
| US 9,399,072 | Methods of Treatment of Pancreatic Cancer In force · High confidence | Abraxis Bioscience, LLC | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.